Mutation Testing for Colorectal Cancer
Cathy Eng, professor and director, Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, says mutation testing is done to determine which, if any, therapies could be used in addition to chemotherapy.
KRAS mutations are very common — occurring in about 30 to 50 percent of patients — and can help a physician steer away from certain expensive drugs.
BRAF mutations are not common and occur in about 5 to 8 percent of patients. A BRAF mutation signifies to a physician that a patient must be treated aggressively upfront.
Unfortunately, Eng says, not all mutations can be targeted with a specific drug.
The Sport of Cancer: How One Survivor Linked Ironman Training and Colorectal Cancer
February 16th 2023Teri Griege completed an Ironman triathlon in 2009, and less than a month later received a stage 4 colorectal cancer diagnosis. In this episode of Cancer Horizons, she shared her story.
Listen
‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC
January 27th 2022In this episode of the “Cancer Horizons” podcast, a woman living with colorectal cancer who was diagnosed 14 years ago at age 29 discusses what it was like to be the youngest person in the treatment room, and how she found another community of young survivors.
Listen
